Reports preliminary Q2 revenue $795M-$798M, consensus $810.11M. Bruker (BRKR) estimates that its non-GAAP organic revenue in the second quarter of 2025 declined approximately 7% year-over-year, with constant-exchange rate revenue declining approximately 3%. Second quarter 2025 bookings reflect weak academic demand, as well as softness in the U.S. biopharma market. Second quarter 2025 non-GAAP EPS is expected in the $0.32 – $0.34 range, representing approximately a $0.19 per share decline year-over-year, including a $0.06 foreign currency headwind.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target lowered to $50 from $61 at BofA
- NIH directs staff not to end any extra research projects for now, NY Times says
- Bruker’s Growth Potential Driven by Innovations and Strategic Cost Management
- Bruker acquires biocrates life sciences, terms undisclosed
- Bruker launches new timsUltra AIP system